Our Latest News

Cambridge, UK – January 23, 2020 BioMed Realty (“BioMed Realty” or the “Company”), a Blackstone portfolio company and a leading provider of real estate solutions to the life sciences community, and RxCelerate, one of the leading out-sourced drug discovery and...

Cambridge, UK and Cambridge, MA Tuesday 22nd November 2022, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today announced the acquisition of drug discovery company Methuselah Health UK Ltd for an undisclosed sum....

Cambridge, UK and Cambridge, MA – Tuesday 19th July 2022, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new small molecule discovery platform, RxNfinity™, that leverages machine learning,...

Cambridge, UK and Cambridge, MA – Tuesday 16th February 2021, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Galaxy™, that offers significant advantages over...

Cambridge, UK – January 23, 2020 BioMed Realty (“BioMed Realty” or the “Company”), a Blackstone portfolio company and a leading provider of real estate solutions to the life sciences community, and RxCelerate, one of the leading out-sourced drug discovery and...

RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today that it has acquired UK-based molecular modelling company Prosarix.   Originally founded in 2006, Prosarix has built a reputation as one of the...